News & Events
- Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
- Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
- Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- Publication of Half-year report 2024
- Genetic Analysis AS: Publication of Half-year report 2024
- Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises
- Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology
- Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
- Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
- Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
- Minutes from the Extraordinary General Meeting 17 July 2024 in Genetic Analysis AS
- Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024
- Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises